A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Samumed
- 13 Nov 2019 Results of pooled analysis from NCT02095548, NCT03122860 and NCT02536833 studies, presented in a Samumed media release.
- 13 Nov 2019 Accordng to a Samumed media release, results of post hoc analysis from the study, and safety data pooled from this and NCT02095548, NCT02536833 studies were presented at the 2019 American College of Rheumatology (ACR) Annual Meeting.
- 15 Jun 2019 Results (n= 635) of post hoc analysis from a phase 2b trial presented at the 20th Annual Congress of the European League Against Rheumatism